Literature DB >> 8050864

Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis.

R Sandyk1, G I Awerbuch.   

Abstract

Multiple sclerosis (MS) is the most common of the demyelinating diseases of the CNS. The clinical course and prognosis of the disease are variable. Characteristically, the illness tends to progress in a series of relapses and remissions. Over the years there is a tendency for the patient to enter a phase of slow and steady deterioration of neurologic function. In about 10%-20% of patients, the course of the disease is not punctuated by a fluctuating course, but rather by an inexorable progression from the onset. The pineal gland has been implicated recently in the pathogenesis and clinical course of MS. Since MS is generally a chronic progressive disorder, we predicted an association between duration of illness and the activity of the pineal gland. To investigate this hypothesis further, we studied nocturnal plasma melatonin levels in relation to duration of illness in a cohort of 32 MS patients (4 men, 28 women; mean age: 41.1 years; SD = 11.1; mean duration of illness: 13.1 years; SD = 12.4) randomly selected from consecutive hospital admissions to a Neurology service for exacerbation of symptoms. For the purpose of comparison, we also studied in the sample serum prolactin levels. The cohort included 7 patients in whom the duration of illness since onset of first neurological symptoms was < or = 5 years (mean: 3.0 years +/- 1.1) and a cohort of 25 patients in whom the duration of illness was > 5 years (mean: 15.6 years +/- 12.7).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050864     DOI: 10.3109/00207459408986306

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  4 in total

1.  Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Authors:  Simone Kern; Michael Geiger; Madlen Paucke; Alina Kästner; Katja Akgün; Tjalf Ziemssen
Journal:  J Mol Med (Berl)       Date:  2019-08-30       Impact factor: 4.599

Review 2.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

3.  Serum Prolactin Levels in Multiple Sclerosis, Neuromyelitis Optica, and Clinically Isolated Syndrome Patients.

Authors:  Recai Türkoğlu; Murat Giriş; Mehmet Gencer; Uğur Akcan; Arda Örçen
Journal:  Noro Psikiyatr Ars       Date:  2016-12-01       Impact factor: 1.339

4.  Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients.

Authors:  Auda Fares
Journal:  J Cardiovasc Dis Res       Date:  2011-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.